The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1320
Prasugrel (Effient) vs. Clopidogrel (Plavix)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved prasugrel (Effient – Lilly/Daiichi Sankyo), an oral antiplatelet drug, for use with aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndromes (ACS) being managed with percutaneous coronary intervention (PCI).1 It will compete with clopidogrel (Plavix) for such use.2,3

PHARMACOLOGY — Prasugrel is a thienopyridine prodrug that must undergo hydrolysis by intestinal esterases and oxidation by CYP3A4 and CYP2B6 to be converted to its active metabolite. The active metabolite binds to the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets, leading to irreversible inhibition of platelet activity for the 7-10 day lifespan of the platelet. Genetic reducedfunction polymorphisms, which may interfere with conversion of clopidogrel by CYP2C19 to its active form in as many as 30% of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Prasugrel (Effient) vs. Clopidogrel (Plavix)
Article code: 1320a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian